Asian Science Citation Index is committed to provide an authoritative, trusted and significant information by the coverage of the most important and influential journals to meet the needs of the global scientific community.  
ASCI Database
308-Lasani Town,
Sargodha Road,
Faisalabad, Pakistan
Fax: +92-41-8815544
Contact Via Web
Suggest a Journal
Articles by Peter Wilson
Total Records ( 2 ) for Peter Wilson
  Ngoc-Anh Le , Monica Farkas-Epperson , Ran Jin , Andrew M. Tershakovec , David R. Neff , Robert Wolfert , Joanne E. Tomassini and Peter Wilson
  High levels of lipoprotein-associated phospholipase A2 (LpPLA2) are associated with increased risk of cardiovascular disease. LpPLA2 is an inflammatory enzyme marker and is less prone to effects of systemic infection as are other inflammatory markers such as C-reactive protein (hsCRP). In a previously reported study, co-administration of ezetimibe/simvastatin (E/S) 10/20 mg with extended-release niacin up to 2 g/day (N) reduced low-density lipoprotein cholesterol and increased high-density lipoprotein cholesterol levels significantly more than E/S and N alone in patients with type IIa/IIb hyperlipidemia (T2HLP) during 24 weeks.
  Ngoc-Anh Le , Ran Jin , Andrew M. Tershakovec , David R. Neff , Joanne E. Tomassini , James Otvos and Peter Wilson
  Intervention with concomitant high-density lipoprotein cholesterol (HDL-C)−raising and low-density lipoprotein cholesterol (LDL-C)−lowering therapies may be beneficial in reducing cardiovascular disease risk. The effects of these therapies on lipoprotein particle numbers have not been well-studied in patients with type II hyperlipidemia (T2HLP). Niacin is currently the most effective agent available for increasing HDL-C and also modestly reduces TG, Lp(a), and LDL-C. In numerous studies, ezetimibe/simvastatin (E/S) was shown to enhance LDL-C lowering and improve other lipids and hsCRP compared with statin therapy in hypercholesterolemic patients.
Copyright   |   Desclaimer   |    Privacy Policy   |   Browsers   |   Accessibility